

PRIOR AUTHORIZATION CRITERIA

BRAND NAME*
(generic)

ORALAIR

(sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract)

Status: CVS Caremark® Criteria

Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Oralair is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the five grass species contained in this product. Oralair is approved for use in persons 5 through 65 years of age.

Oralair is not indicated for the immediate relief of allergy symptoms.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed as immunotherapy for the treatment of grass pollen-induced allergic rhinitis
AND
 - The request is NOT for continuation of therapy
AND
 - The diagnosis has been confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the 5 grass species (sweet vernal, orchard, perennial rye, timothy, kentucky blue grass) contained in the requested drug
AND
 - The patient does not have ANY of the following: A) Severe, unstable or uncontrolled asthma, B) History of any severe systemic allergic reaction, C) History of any severe local reaction to sublingual allergen immunotherapy, D) History of eosinophilic esophagitis
AND
 - The requested drug is being prescribed by, or in consultation with, an allergist or immunologist
 - OR**
 - The request is for continuation of therapy
AND
 - The patient has achieved or maintained improvement in rhinoconjunctivitis symptoms (e.g., runny nose, stuffy nose, sneezing, itchy nose, gritty/itchy eyes, watery eyes), OR the patient had a reduction in use of allergy symptom-relieving medications (e.g., antihistamines, corticosteroids)

Duration of Approval (DOA):

- 1132-A: DOA: 12 months

REFERENCES

1. Oralair [package insert]. Lenoir, North Carolina: GREER Laboratories, Inc.; November 2023.
2. Lexicomp Online, Lexi-Drugs. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed January 02, 2024.

Oralair PA Policy UDR 02-2024.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 01/02/2024).